Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response

View ORCID ProfileKarthik Ramasamy, Ross Sadler, Sally Jeans, Paul Weeden, Sherin Varghese, Alison Turner, Jemma Larham, Nathanael Gray, Oluremi Carty, Joe Barrett, Stella Bowcock, Udo Oppermann, Gordon Cook, Chara Kyriakou, Mark Drayson, Supratik Basu, Sally Moore, Sarah McDonald, Sarah Gooding, Muhammad K Javaid
doi: https://doi.org/10.1101/2021.10.21.21265158
Karthik Ramasamy
1Oxford University Hospitals NHS Trust, Radcliffe department of Medicine, Oxford University, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Karthik Ramasamy
  • For correspondence: karthik.ramasamy@ndcls.ox.ac.uk
Ross Sadler
2Department of Immunology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally Jeans
3The Botnar Research Centre, Windmill Road, Headington, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Weeden
3The Botnar Research Centre, Windmill Road, Headington, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sherin Varghese
4Late Phase Haematology, Oxford University Hospital NHS Foundation Trust, Churchill Hospital, Churchill Drive, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alison Turner
5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jemma Larham
6Oxford University Hospitals NHS Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathanael Gray
5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oluremi Carty
2Department of Immunology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joe Barrett
5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stella Bowcock
7Princess Royal University Hospital, King’s College Hospital Foundation NHS Trust, Farnborough Common, Orpington, Kent, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Udo Oppermann
5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon Cook
8NIHR Leeds Medtech & In vitro Diagnostics Cooperative, Leeds Teaching Hospitals Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chara Kyriakou
9Department of Haematology, University College London Hospitals NHS Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Drayson
10College of Medical and Dental Sciences Medical School, University of Birmingham, Edgbaston, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Supratik Basu
11University of Wolverhampton, The Royal Wolverhampton NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally Moore
12Oxford University Hospitals NHS Trust NHS Foundation Trust, Oxford and Bath Royal United Hospitals, Bath, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah McDonald
13Myeloma UK, Beaverbank Business Park, Edinburgh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Gooding
14MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
15Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muhammad K Javaid
5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Background Myeloma patients frequently respond poorly to bacterial and viral vaccination. A few studies have reported poor humoral immune responses in myeloma patients to COVID-19 vaccination.

Methods Using a prospective study of myeloma patients in UK Rudy Study cohort, we assessed humoral and Interferon gamma release assay (IGRA) cellular immune responses to COVID-19 vaccination post second COVID-19 vaccine administration.

Findings We report data from 214 adults with myeloma (n=204) or smouldering myeloma (n=10) who provided blood samples at least 3 weeks after second vaccine dose. Positive Anti-Spike antibody levels (> 50 IU/ml) were detected in 189/203 (92.7%), positive IGRA responses were seen in 97/158 (61.4%) myeloma patients. Only 10/158 (6.3%) patients were identified to have both a negative IGRA and negative Anti-Spike protein antibody response. 95/158 (60.1%) patients produced positive results for both anti-Spike protein serology and IGRA. After adjusting for disease severity and myeloma therapy, poor humoral immune response was predicted by male gender. Predictors of poor IGRA included anti-CD38/ anti-BCMA therapy and Pfizer-BioNTech (PB) vaccination.

Interpretation Significant majority of myeloma patients elicit Anti-Spike protein antibody responses to COVID-19 vaccine with 60% of myeloma patients showing both humoral and T cell response. Predictors of a poor immune response included male gender, myeloma therapy regimen and administration of Pfizer-BioNTech vaccination. Further work is required to understand the clinical significance of divergent cellular response to vaccination.

Funding Funding for this study has been received from Blood Cancer Vaccine Consortium and Janssen UK. RUDY platform has been funded by NIHR.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding: Funding for this study has been received from Blood Cancer Vaccine Consortium and Janssen UK. RUDY platform has been funded by NIHR.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval: The study is based on the existing RUDYstudy.org platform (LREC 14/SC/0126 & RUDY LREC 17/SC/0501), an established online rare disease platform with online dynamic consent and patient reported outcome assessments. IRAS no: 213780, RUDY study Minor amendment 3, HRA approval 28th January 2021 given by NHS HRA South Central - Berkshire B Research Ethics Committee.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 25, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response
Karthik Ramasamy, Ross Sadler, Sally Jeans, Paul Weeden, Sherin Varghese, Alison Turner, Jemma Larham, Nathanael Gray, Oluremi Carty, Joe Barrett, Stella Bowcock, Udo Oppermann, Gordon Cook, Chara Kyriakou, Mark Drayson, Supratik Basu, Sally Moore, Sarah McDonald, Sarah Gooding, Muhammad K Javaid
medRxiv 2021.10.21.21265158; doi: https://doi.org/10.1101/2021.10.21.21265158
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response
Karthik Ramasamy, Ross Sadler, Sally Jeans, Paul Weeden, Sherin Varghese, Alison Turner, Jemma Larham, Nathanael Gray, Oluremi Carty, Joe Barrett, Stella Bowcock, Udo Oppermann, Gordon Cook, Chara Kyriakou, Mark Drayson, Supratik Basu, Sally Moore, Sarah McDonald, Sarah Gooding, Muhammad K Javaid
medRxiv 2021.10.21.21265158; doi: https://doi.org/10.1101/2021.10.21.21265158

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Hematology
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8790)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1864)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (492)
  • Hematology (207)
  • HIV/AIDS (395)
  • Infectious Diseases (except HIV/AIDS) (10567)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1756)
  • Nursing (103)
  • Nutrition (266)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (965)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (219)
  • Psychiatry and Clinical Psychology (1845)
  • Public and Global Health (3986)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (535)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)